submitted 8 days ago by okuhle34
- A study suggests that the six-monthly anti-HIV jab, lenacapavir, could be beneficial for public health, but the US government's funding cuts are jeopardizing its availability in countries like South Africa.
- Lenacapavir has shown promising results in preventing HIV infections, especially among teen girls and young women, but uncertainties remain about its cost and availability due to funding challenges.
Advertisement
No comments yet
Be the first to share your opinion!
Related Posts
